NL-OMON56376撤回不适用
Towards optimal treatment for high risk prostate cancer; stereotactic pelvic radiotherapy with focal boost to the primary tumor - HypoPRIME
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Men (aged >=18 years of age) diagnosed within 6 months before inclusion with
- •high risk prostate cancer:
- •o T3 based on digital rectal examination AND/OR
- •o Grade >= 4 AND/OR
- •o PSA >=20 ug/L
- •- Indication for elective lymph node irradiation (based on current clinical
- •guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)
排除标准
- •Prior pelvic radiotherapy
- •TransUrethral Resection of the Prostate (TURP) < 3 months ago
- •Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU,
- •cryotherapy, etc)
- •contraindications to MRI
- •no visible lesion on MRI in prostate for boost
- •no PSMA-PET scan
- •inflammatory bowel disease
- •metastatic disease (M1)
- •unsuitable for SBRT or WPRT
- •medical history of cancer other than basal cell carcinoma of the skin
研究者
相似试验
招募中
不适用
Towards Optimal Treatment for High Risk Prostate CancerHigh Risk Prostate CarcinomaNCT06204341Haaglanden Medical Centre207
招募中
3 期
Evaluating the Utility of a Patient Decision Aid for Prospective Participants in the Trans-Tasman Radiation Oncology Group Radiotherapy - Adjuvant Versus Early Salvage Prostate Cancer TrialACTRN12611001024932Psycho-Oncology Cooperative Research Group (PoCoG)150
招募中
1 期
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerCTIS2022-501551-90-00Gasthuiszusters Antwerpen493
已完成
不适用
ifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapyMen with advanced prostate cancer receiving androgen suppression therapyMalignant neoplasm of prostateCancerISRCTN88605738Sheffield Teaching Hospitals NHS Foundation Trust (UK)100
招募中
2 期
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersProstate CancerNCT06282588Cancer Research Antwerp493